Is it safe?
Can ARWR take a bad year?
Arrowhead Pharmaceuticals, Inc. holds $1.56B more cash than debt, and is burning $19M a quarter, about 21.3 years of cover.
$1.56B
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 7.44
Altman Z-score · safe zone, above 3
- Cash runway
- 5+ years
Cash runway · burning $19M a quarter at the current rate
Details›
- Total debtQ3 2026
- $40M
- Cash and short-term investments
- $1.60B
- Net cash
- $1.56B
- EBITDA, trailing twelve months
- −$202M
- Operating profit, trailing twelve months
- −$226M
- Debt / equity
- 0.09×
- Annualised volatilitytwo years of daily moves
- 67%
- Worst drawdown on file
- −89%
- Below its 52-week high
- −0.60%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.